Sanfran, that is a wise perspective.

It sure has made me wonder why AZ has not jumped on this. However, I was looking at the issue of cystic fibrosis and from what I understood they only started looking at epigenetic solutions perhaps 12 years ago and with little success. I sort of assumed that epigenetics would be the obvious path to treat auto-immune diseases.

So what I am thinking is the following;

1. Epigenetics is relatively new in medical terms (as opposed to the scientific community)
2. From what I recall, AZ kicked the tires at Resverlogix 7 or 8 years ago, long before the recent trials and analytical work. Perhaps there was a bad taste.
3. AZ, from what I've read, has been going through significant turmoil at both the portfolio and management levels.
4. It strikes me that BP is averse to "big" risk!
5. Finally, drug developers can be bought up easily but not at the price that Eastern, NGN and Don are willing to give it up at. Therefore, given what I believe the CVR might look like in order for a sale to happen, if I were the acquirer I would want to be very certain of a victory because they don't want to take the chance of losing billions.

When I've looked at some of the biotech buyouts they look like peanuts compared to social and digital media IPOs.

That fact that Hepalink came in gives me confidence. However, they are very smart because they came in to kick the tires, get inside information and they did it at a very low cost and yet their potential upside is billions in revenue and profit for at least 13 years.

I always find your posts valuable.

I'm long and confident but of course frustrated by the time science requires to move forward.

GLTA

Cheers

Toinv :)